Literature DB >> 19759221

Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results.

A Van Deun1, L Barrera, I Bastian, L Fattorini, H Hoffmann, K M Kam, L Rigouts, S Rüsch-Gerdes, A Wright.   

Abstract

The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n = 6) or susceptible (S) (n = 2) or probably resistant (PR) (n = 8) or susceptible (PS) (n = 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Löwenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759221      PMCID: PMC2772627          DOI: 10.1128/JCM.01209-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance.

Authors:  H Traore; K Fissette; I Bastian; M Devleeschouwer; F Portaels
Journal:  Int J Tuberc Lung Dis       Date:  2000-05       Impact factor: 2.373

2.  Heteroresistance in Mycobacterium tuberculosis.

Authors:  H Rinder; K T Mieskes; T Löscher
Journal:  Int J Tuberc Lung Dis       Date:  2001-04       Impact factor: 2.373

3.  Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa.

Authors:  Marinus Barnard; Heidi Albert; Gerrit Coetzee; Richard O'Brien; Marlein E Bosman
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

4.  Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan.

Authors:  Hsing-Yu Hwang; Chung-Yu Chang; Lin-Li Chang; Shui-Feng Chang; Ya-Hui Chang; Yi-Jing Chen
Journal:  J Med Microbiol       Date:  2003-03       Impact factor: 2.472

5.  Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India.

Authors:  Noman Siddiqi; Mohammed Shamim; Seema Hussain; Rakesh Kumar Choudhary; Niyaz Ahmed; Sharmistha Banerjee; G R Savithri; Mahfooz Alam; Niteen Pathak; Amol Amin; Mohammed Hanief; V M Katoch; S K Sharma; Seyed E Hasnain
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  L K Yuen; D Leslie; P J Coloe
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

7.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.

Authors:  M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

8.  Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.

Authors:  A Laszlo; M Rahman; M Espinal; M Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2002-09       Impact factor: 2.373

9.  Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts.

Authors:  Stephen H Gillespie; Owen J Billington; Aodhan Breathnach; Timothy D McHugh
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431

10.  Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis.

Authors:  Deneke H Mariam; Yohannes Mengistu; Sven E Hoffner; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  91 in total

1.  Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries.

Authors:  Kanchan Ajbani; Shou-Yean Grace Lin; Camilla Rodrigues; Duylinh Nguyen; Francine Arroyo; Janice Kaping; Lynn Jackson; Richard S Garfein; Donald Catanzaro; Kathleen Eisenach; Thomas C Victor; Valeru Crudu; Maria Tarcela Gler; Nazir Ismail; Edward Desmond; Antonino Catanzaro; Timothy C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa.

Authors:  L E Scott; N Gous; B E Cunningham; B D Kana; O Perovic; L Erasmus; G J Coetzee; H Koornhof; W Stevens
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

3.  Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008.

Authors:  Pawan K Angra; Thomas H Taylor; Michael F Iademarco; Beverly Metchock; J Rex Astles; John C Ridderhof
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

4.  First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances.

Authors:  Valeriu Crudu; Ecaterina Stratan; Elena Romancenco; Vera Allerheiligen; Andreas Hillemann; Nicolae Moraru
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

5.  Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding.

Authors:  Soumitesh Chakravorty; Harsheel Kothari; Bola Aladegbami; Eun Jin Cho; Jong Seok Lee; Sandy S Roh; Hyunchul Kim; Hyungkyung Kwak; Eun Gae Lee; Soo Hee Hwang; Padmapriya P Banada; Hassan Safi; Laura E Via; Sang-Nae Cho; Clifton E Barry; David Alland
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

6.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

7.  Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance.

Authors:  Akos Somoskovi; Vanessa Deggim; Diana Ciardo; Guido V Bloemberg
Journal:  J Clin Microbiol       Date:  2013-07-12       Impact factor: 5.948

8.  Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany.

Authors:  Sönke Andres; Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

9.  Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations.

Authors:  N N Abanda; J Y Djieugoué; V S Khadka; E W Pefura-Yone; W F Mbacham; G Vernet; V M Penlap; Y Deng; S I Eyangoh; D W Taylor; R G F Leke
Journal:  Clin Microbiol Infect       Date:  2017-12-05       Impact factor: 8.067

10.  Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Andrea M Cabibbe; Emanuele Borroni; Massimo Degano; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.